Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Observational × empagliflozin × Clear all

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Conditions

Diabetes Mellitus, Type 2 1

Interventions

Blood Specimen Collection 31 Sorafenib 29 Nivolumab 29 Bevacizumab 26 Data Collection 24 Observation 23 palbociclib 22 Sunitinib 22 radium Ra 223 dichloride 20 enzalutamide 18 Rituximab 18 Ipilimumab 16 regorafenib 15 Drug Therapy 15 Trastuzumab 14 Docetaxel 14 ribociclib 12 exemestane 12 atezolizumab 12 apalutamide 11 Standard of Care 11 Leuprolide 11 Capecitabine 11 Afatinib 11 darolutamide 10 Bortezomib 10 Anastrozole 10 trastuzumab deruxtecan 9 pembrolizumab 9 avelumab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03464045 2025-04-20

Empa PASS on Urinary Tract Malignancies

Boehringer Ingelheim

344,995 enrolled 12 charts

Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡